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Purpose: To examine the course of depression and anxiety in patients with temporal lobe epilepsy (TLE) treated with epilepsy
surgery (and anticonvulsant drugs) or medical means alone.
Methods: Of 94 TLE patients evaluated for epilepsy surgery, 76 underwent a resective procedure, 18 continued on medical
treatment alone. Depression (Beck Depression Inventory (BDI)) and anxiety scores (Self-Rating Anxiety Scale (SRAS)) were
examined during presurgical evaluation (T1) and after a mean of 16 months (T2), or 12 months after surgery. Depression and
anxiety scores were related to type of intervention, underlying epileptogenic lesion, change of seizure control and anticonvulsant
therapy.
Results: At T1, depression and anxiety scores were higher in patients with TLE than scores in published normal populations.
At T2, depression but not anxiety scores were significantly lower than at T1. Change of depression scores interacted with
improvements of seizure control.
Conclusions: Evidence of depression and anxiety is commonly found in patients with TLE. Depression improves not because
of epilepsy surgery per se, but because of improved seizure control. This is more commonly achieved by surgery than medical
treatment. The results are consistent with the hypothesis that depression in TLE is caused by pathological epileptic activity rather
than a fixed structural defect.
© 2003 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Depression and anxiety are the most common psy-
chiatric disorders in patients with epilepsy, and their
prevalence is increased compared to the general
population1, 2. Psychiatric symptoms contribute to the
reduction of quality of life and cognitive function
found in patients with epilepsy3, 4, and they are one
cause of the increased risk of self-harm, parasuicide
and completed suicide in this patient group5–9. The
risk of depression and anxiety may be higher in pa-
tients with epilepsy than in patients with other chronic
or neurological disorders10–12. Psychiatric symptoms
may be more commonly associated with focal, es-
pecially temporal lobe, than idiopathic generalised
epilepsies13–16.
Many patients with temporal lobe epilepsy (TLE)
prove refractory to medical treatment and are consid-
ered for epilepsy surgery. Given the high prevalence
and clinical significance of co-existing psychiatric dis-
orders in these patients the effects of surgery on psy-
chiatric symptoms is highly relevant. Previous studies
have reported improvement17–19, deterioration20, 21,
or no change in postoperative depression and anxiety
prevalence or scores22. However, these studies were
small18, 19, 21, were based on follow-up data gathered
shortly after surgery19, 21, or did not differentiate
between patients with good or poor postoperative
seizure outcome21, 22. With the exception of one ret-
rospective study20, no previous studies have included
a control group of medically treated TLE patients.
Our study was designed to examine the effects of
epilepsy surgery or medical anticonvulsant treatment
on depression and anxiety in patients with TLE.
METHODS
All patients with refractory TLE undergoing in-patient
presurgical evaluation between 1998 and 2000 were
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screened for participation in this study. Patients be-
low the age of 15, and patients with a premorbid
IQ of less than 70 were excluded. In total, 94 pa-
tients fulfilled all inclusion criteria and were willing
to participate. Patients were divided into a group of
76 who underwent TLE surgery, and a group of 18
control subjects who continued on anticonvulsant
treatment alone. They were not randomised to surgi-
cal or medical epilepsy treatment. Of the 76 patients
who underwent surgery, 47% were operated on the
left and 53% on the right temporal lobe, 60% had
a selective amygdalohippocampectomy (SAH), 15%
a standard anterior 2/3 temporal lobe resection and
25% an extended temporal lesionectomy. The sur-
gical techniques used in the operated patients have
been described elsewhere23, 24. Histological diag-
noses included ammonshorn sclerosis (AHS, 63%),
tumor (13%), migration disorder (7%) and other
changes including gliosis and cavernoma (16%).
In one patient, no histopathological results were
available.
The medically treated control group consisted of
nine patients with TLE who decided against an oper-
ation although they were considered good candidates,
and nine patients in whom no reasonable hypothesis
for an operation could be formulated. In these 18 pa-
tients, MRI revealed hippocampal sclerosis in 56%,
and other temporal lobe abnormalities in 22%. MRI
was unremarkable in 22%.
Patients were first examined during in-patient
presurgical investigation (T1). Repeat examination
(T2) was undertaken on an out-patient basis after a
mean of 16 months (SD 3.5). In the surgically treated
patients, T2 was performed 12 months postopera-
tively (SD 3.9). Depression and anxiety levels at T1
and T2 were determined using the Beck Depres-
sion Inventory25 (BDI) and the Self-Rating Anxiety
Scale26 (SRAS). Patients were categorised as ‘proba-
bly depressed’ if they had a sum BDI score of greater
than 12. This threshold was chosen because a large
previous study (N = 1250) showed that the sensitiv-
ity and specificity of this score for clinical depression
are 100 and 99%, respectively27. Following the sug-
gestion of the authors of the test, an SRAS score of
greater than 35 was defined as evidence of clinically
relevant ‘abnormal anxiety’26.
To describe seizure outcome at T2, patients were
categorised as follows: (1) completely seizure free,
(2) greater than 50% reduction of the frequency of
seizures involving loss of consciousness, and (3) less
than 50% reduction of seizures with loss of conscious-
ness. Medical anticonvulsant treatment was described
using the categories monotherapy and polytherapy.
Psychiatric medications were divided into antide-
pressant and anxiolytic drugs. No patient received
antipsychotic medication.
Multivariate covariance analysis for repeat mea-
surements (MANCOVA) was used to look for inter-
action effects between both affective scores (BDI and
SRAS) and treatment (surgical/medical) or change
of seizure frequency between T1 and T2 in percent.
Chi-squared tests (χ2-tests) were performed to test
the significance of effects of binary variables (e.g.
sex, monotherapy or polytherapy). Ordinal or not
normally distributed data were compared with the
Mann–Whitney U-test for independent samples. Con-
tinual, normally distributed data were analysed using
t-tests. Multiple stepwise regression analysis was per-
formed to identify possible predictors of change of
affective scores over time. Findings were reported
as significant with P < 0.05 and as a trend with
P < 0.10.
RESULTS
At T1 there were no significant differences between
the surgically or medically treated groups of TLE
patients with regard to age, sex, IQ, anticonvulsant
monotherapy or polytherapy, medical treatment for
anxiety or depression, seizure frequency, age at onset
or duration of epilepsy (Table 1). There was a dif-
ference between the groups in terms of lateralisation
of the epileptogenic cerebral lesion as determined
by MRI: there were significantly more patients with
evidence of bilateral or right-sided lesions in the
medically treated group.
There was no significant difference between the T1
and T2 latency in the two groups. At T2, significantly
more patients in the surgically treated group had ex-
perienced an improvement in seizure frequency (χ2 =
55.857; P < 0.001), and a reduction of their anticon-
vulsant therapy (χ2 = 9.209; P = 0.010). The major-
ity of medically treated patients continued to receive
pharmacological polytherapy and seizure frequency
remained unchanged (Table 2).
Depression and anxiety scores at T1
At T1, patients in the surgical group had significantly
higher depression scores than a group of healthy
German subjects (T = 3.838; P < 0.001)28; pa-
tients continuing on medical treatment only showed
a trend towards higher depression scores (T = 2.062;
P = 0.056). Twenty-nine percent of surgically and
18% of medically treated patients had a BDI sum
score greater than 12. Neither the difference be-
tween the frequency of a score elevated to this level
(χ2 = 0.903; P = 0.342) nor the difference in mean
sum BDI scores (T = −0.104; P = 0.918) between
the two patient groups was statistically significant.
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Table 1: Demographic and clinical patient characteristics at T1.
Epilepsy surgery (N = 76) Medical treatment (N = 18) Significance (two-tailed)
Age, mean (SD) 35.0 (9.0) 35.8 (10.1) n.s.b
Sex (male/female) 33/43 9/9 n.s.a
IQ, mean (SD) 101.0 (13.1) 98.5 (12.2) n.s.b
Medical treatment
Anticonvulsants
None (N) 1% (1) 0% (0) n.s.a
Monotherapy (N) 20% (15) 28% (5)
Polytherapy (N) 79% (60) 72% (13)
Antidepressants
Yes (N) 3% (2) 11% (2) n.s.a
No (N) 97% (74) 89% (16)
Anxiolytics
Yes (N) 24% (16) 11% (2) n.s.a
No (N) 76% (60) 89% (16)
Seizure frequency per year, mean (SD) 110.9 (214.5) 132.2 (188.7) n.s.b
Age at onset, mean (SD) 13.1 (9.0) 11.2 (6.6) n.s.b
Duration of epilepsy in years, mean (SD) 22.0 (11.7) 24.8 (10.1) n.s.b
Lateralisation of cerebral lesion (MRI)
Bilateral (N) 0% (0) 11% (2)
Right (N) 47% (36) 28% (5) P = 0.007a
Left (N) 53% (40) 61% (11)
n.s., not significant.
aχ2-test; b Mann–Whitney U-test.
Table 2: Change of seizure frequency and medical therapy.
Epilepsy surgery (N = 76) Medical treatment (N = 18) Significance (two-tailed)a
Change of seizure frequency
Seizure-free (N) 75% (57) 5% (1) P < 0.001
>49% improvement (N) 20% (15) 11% (2)
<50% improvement or worse (N) 5% (4) 84% (15)
Change of anticonvulsant therapy
Fewer anticonvulsants (N) 43% (33) 5% (1) P = 0.01
No change (N) 49% (37) 78% (14)
More anticonvulsants (N) 8% (6) 17% (3)
Change of antidepressant therapy
Started (N) 3% (2) 5% (1) n.s.
No change (N) 91% (69) 95% (17)
Discontinued (N) 6% (5) 0% (0)
Change of anxiolytic therapy
Started (N) 17% (13) 5% (1) n.s.
No change (N) 79% (60) 78% (14)
Discontinued (N) 4% (3) 17% (3)
a χ2-test.
At T1 both, operated (T = 7.932; P < 0.001)
and conservatively treated patients (T = 4.081; P =
0.001) had significantly higher anxiety scores than a
population of 489 healthy German controls who had
a mean SRAS score of 27.529. Based on a previously
determined SRAS threshold score of 3526, 48% of pa-
Table 3: Mean depression and anxiety scores and standard deviations at T1.
Surgical treatment (N = 76) Medical treatment (N = 18) t-value Significance (two-tailed)a
Depression (BDI) 10.07 (8.21) 8.41 (3.92) −0.104 n.s.
Anxiety (SRAS) 34.68 (8.11) 34.78 (7.57) 0.036 n.s.
n.s., not significant.
a t-test for independent samples.
tients in the surgical and 39% in the conservative treat-
ment groups were considered ‘abnormally anxious’.
Mean SRAS scores (T = 0.036; P = 0.971) and the
frequency patients with ‘abnormal anxiety’ in the two
TLE groups (χ2 = 0.485; P = 0.486) did not differ
significantly (Table 3).
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Fig. 1: Proportion of 76 surgically and 18 medically treated
patients with TLE, ‘probable depression’ and ‘abnormal
anxiety’ at the time of the initial assessment (T1) and 16
months (SD 3.5) later (T2).
Depression scores at T2
At T2, the mean depression scores of patients with
surgically treated TLE were not significantly different
from those of a healthy German control population28
(T = 0.300; P = 0.765), whereas scores in medi-
cally treated patients were significantly elevated (T =
3.916; P = 0.001).
The proportion of patients with a BDI > 12 at T2
was significantly smaller in the surgically than in the
medically treated group (16% vs. 41%, χ2 = 5.508;
P = 0.019). Whereas the number of patients cate-
Table 4: Mean depression and anxiety scores at T1 and T2 and relation between seizure control.
T1 T2 t-value Significance (two-tailed)a
Depression
<50% improved, mean (SD) 8.3 (3.7) 12.9 (6.4) −2.26 P = 0.037
>49% improved, mean (SD) 10.4 (5.9) 7.9 (6.7) 2.28 P = 0.036
Seizure-free, mean (SD) 10.0 (8.9) 6.0 (6.9) 4.33 P < 0.001
Anxiety
<50% improved, mean (SD) 33.6 (5.7) 36.8 (6.7) −3.07 P = 0.007
>49% improved, mean (SD) 33.8 (8.2) 32.2 (6.5) 0.74 n.s.
Seizure-free, mean (SD) 35.6 (8.5) 33.9 (7.6) 1.68 n.s.
n.s., not significant.
a t-test for dependent samples.
gorised as ‘probably depressed’ dropped significantly
in the surgical group (Sign-test, P = 0.021), there
was a non-significant increase of depressed patients
in the medical group (P = 0.289) (Fig. 1). Seven-
teen percent of patients who had undergone epilepsy
surgery and 12% of patients treated medically who
had BDI scores greater than 12 at T1 dropped below
this threshold at T2. On the other hand, 4% of surgical
and 35% of medical patients who were not categorised
as ‘probably depressed’ at T1 became so at T2.
Regardless of treatment mode, a significant re-
lationship between seizure control and change in
depression scores could be demonstrated (Table 4).
Patients whose seizure frequency had improved by
less than 50% or whose seizures were worse had
significantly higher depression scores at T2 than at
T1 (T = −2.261; P = 0.037). However, depression
scores at T2 were significantly lower than at T1 in
patients who had at least 50% improvement in seizure
frequency (T = 2.284; P = 0.036) or in patients who
became seizure-free (T = 4.327; P < 0.001).
Anxiety scores at T2
Anxiety scores in both treatment groups remained
significantly higher at T2 than those of healthy con-
trols (surgical group: T = 7.872; P < 0.001, medical
group: T = 3.869; P = 0.001). At T2, 39% of sur-
gically and 56% of medically treated patients had a
SRAS score above the predefined threshold for ‘abnor-
mal anxiety’. The prevalence of ‘abnormal anxiety’
in the two patient groups at T2 did not differ signifi-
cantly (χ2 = 1.700; P = 0.192). In neither group was
the prevalence of ‘abnormal anxiety’ significantly dif-
ferent from T1 (Sign-test, surgical group: P = 0.248,
medical group: P = 0.375) (Fig. 1). Twenty-three
percent of surgically and 6% of medically treated pa-
tients above the threshold at T1 had SRAS scores of
35 or less at T2. On the other hand, 13% of surgically
and 22% of medically treated patients who were not
‘abnormally anxious’ at T1 had become so at T2. T2
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scores only differed significantly from T1 scores in pa-
tients who had experienced a deterioration of seizures
or a less than 50% improvement of seizure frequency
(Table 4). In this group, scores increased significantly
from T1 to T2 (T = −3.074; P = 0.007).
Multivariate analysis of affective scores
(BDI and SRAS)
Multivariate analysis revealed significant interactions
between change in affective scores between T1 and
T2 and change in seizure frequency (Hotelling’s F =
4.365; P = 0.016). However, neither repeat mea-
surement (affective scores at T1 and T2, Hotelling’s
F = 0.148; P = 0.862) nor the in-between group
factor (surgical/non-surgical treatment, Hotelling’s
F = 2.106; P = 0.128) or the covariate (change
of seizure frequency, Hotelling’s F = 0.824; P =
0.442) showed significant main effects. There was a
trend towards a significant interaction between ‘repeat
measurement× in-between group factor’ (Hotelling’s
F = 2.897; P = 0.060). Univariate analysis re-
vealed that the significant interaction effect ‘repeat
measurement× covariate’ depended solely on depres-
sion scores (F = 8.429; P = 0.005) and not anxiety
scores (F = 2.630; P = 0.108).
Multiple linear regression analysis of
depression scores
Multiple linear regression analysis revealed that the
change of depression scores between T1 and T2
was affected by the degree of seizure improvement
(T = 2.439; P = 0.017), the seizure frequency at T2
(T = −2.190; P = 0.031), and the BDI score at T1
(T = 2.721; P = 0.008). This means that depres-
sion scores improved most in the patients with the
highest pre-operative BDI scores, the greatest seizure
reduction after surgery and the best seizure control at
the time of T2. Taken together these three variables
explained 36% of the variance of change in BDI.
Age at the time of the test, sex, IQ, age of onset of
epilepsy, duration of epilepsy, interval between T1
and T2, change of anticonvulsant and antidepressive
treatment category, side of cerebral pathology, diag-
nosis of AHS, abnormal MRI or mode of treatment
(not taking into account seizure control) did not affect
BDI scores at T2.
Use of medical treatments for depression
and anxiety
At T1 four patients (4%) used antidepressants, 20
patients (21%) anxiolytic drugs. There was no sig-
nificant difference in terms of use of psychotropic
medications between the two groups (Table 1). At
T2 six patients (6%) took antidepressant drugs, 12
patients (13%) anxiolytic agents. There was no sig-
nificant difference in the change of psychiatric med-
ications for depression (χ2 = 1.59; P = 0.450) or
anxiety (χ2 = 4.995; P = 0.082) from T1 to T2 be-
tween the groups (Table 2). According to the results
of our multiple linear regression analysis, changes
in antidepressant treatment did not contribute to the
improvements seen in depression scores at T2.
DISCUSSION
Prior to therapeutic intervention (T1), mean depres-
sion and anxiety scores were higher in patients with
TLE than in healthy control populations. Based on
threshold scores determined in other studies26, 27, 27%
of patients had ‘probable depression’ and 46% ‘abnor-
mal anxiety’. At T2, there were no significant changes
of both affective scores in the medically treated TLE
patients. In the surgical group depression but not anx-
iety scores had improved.
It is possible that the test–retest interval of 16 months
(or 12 months after surgery) was too short to detect
improvements in anxiety scores or that the SRAS is not
sufficiently sensitive in the setting of TLE and epilepsy
surgery. However, the lack of change of anxiety scores
observed by us is in line with the findings of a previous
study30 which found that 54% of patients continued
to suffer from significant anxiety symptoms although
78% were seizure-free after TLE surgery.
Postoperative improvements in depression scores
after epilepsy surgery have also been observed in
the past18, 21. In contrast to previous prospective
studies17–19, 21, 22, our study included a control group
of patients with TLE treated with medical means
alone. This allowed us to differentiate between the
effects of temporal lobe surgery and the effects of im-
proved seizure control. Our results reveal that surgery
as such did not improve depression scores. Scores
only dropped after surgical intervention, if seizure
control was improved postoperatively. As clinically
relevant improvements of seizure control between T1
and T2 were achieved in 95% of surgically but only
17% of medically treated patients, improvements in
BDI scores were significantly greater in the surgical
patient group. The correlation between the degree of
improvement of BDI score and seizure control found
here is in line with one previous study18 although it
is in contrast with several others which suggested that
only complete seizure-freedom leads to changes of
depression scores19, 21, 31.
The fact that absolute BDI scores at T1 were cor-
related with the degree of change at T2 has been
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reported before18, 20, and is hardly surprising. Very
low and very high scores offer greater scope for
change than scores in the middle of the BDI scale.
Taken together, our results support the notion that
depression in patients with TLE is predominantly
caused by endogenous factors15. The findings suggest
that the improvement of depression scores was caused
by a reduction of abnormal ictal (and presumably
interictal) epileptic activity rather than the removal
of tissue from, or the deafferentation of neurons
within the temporal lobe. That is to say in TLE pa-
tients, depression seems to be related to pathological
dys-functional processes rather than fixed structural
defects. A purely reactive effect, with patients being
less depressed because of fewer seizures, seems less
likely because anxiety scores did not fall in the same
way.
Psychiatric medications did not explain the improve-
ment of depression scores at T2. However, it was no-
table at both, T1 and T2, that only 4 or 6% of patients
were treated with antidepressants although 27 or 20%
had BDI scores greater than 12 patients. Likewise, the
number of patients with recognised and treated anxi-
ety disorders (T1: 21%; T2: 13%) was much smaller
than the number with SRAS scores above the thresh-
old of 35 (T1: 46%; T2: 42%). In accord with other
studies in patients with epilepsy32, this suggests that
depression and anxiety are under-recognised in this
patient group.
There are several limitations to our results. Patients
undergoing evaluation for epilepsy surgery represent
a highly selected group. Our results should, therefore,
not be extrapolated to other patients with epilepsy.
In view of the proven effectiveness of surgery for
refractory TLE33, it would be unethical to randomise
patients to surgical or medical treatment groups. It is,
therefore, possible that our results were affected by
clinical differences between the two patient groups
(for instance, more patients in the medical group had
bilateral temporal lobe lesions). Despite the high sen-
sitivity and specificity of BDI scores greater than 12
for a clinical diagnosis of depression27, the validity
of self-assessment by questionnaire is necessarily
limited.
With this caveat we conclude that (1) the prevalence
of ‘probable depression’ and ‘abnormal anxiety’ are
increased in patients with refractory TLE; (2) depres-
sion but not anxiety levels can be reduced by thera-
peutic (antiepileptic) intervention; (3) improvements
of depression scores are greater in surgically than in
medically treated patients with previously refractory
TLE, because surgery controls seizures more effec-
tively; (4) depression is not improved by surgery per
se; and (5) depression in patients with TLE seems to
be related to pathological epileptic activity rather than
fixed structural defects.
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